Kieren Mather, MD
Enriched profileVice President, Medical – Incretin and Diabetes Breakthroughs, Early Clinical Research, Eli Lilly and Company · Eli Lilly and Company
Kieren Mather is Vice President, Medical – Incretin and Diabetes Breakthroughs, Early Clinical Research, Eli Lilly and Company at Eli Lilly and Company. OpenAlex indexes 423 publications with 16,851 citations (h-index 58); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Endocrinology, Diabetes & Metabolism profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Kieren Mather, MD, is Vice President, Medical – Incretin and Diabetes Breakthroughs, Early Clinical Research, Eli Lilly and Company. The public record shows 423 publications with 16,851 citations (h-index 58), centered on Type 2 Diabetes, Obesity. It also documents an investigator role on 6 registered clinical trials, 8 NIH-funded awards (2003–2018).
- Most recent indexed publication: 2026 · Diabetes, obesity & metabolism
- Top research focus: Type 2 Diabetes
- 6 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 25 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- A Novel Positron Emission Tomography (PET) Approach to Measuring Myocardial Metabolism
Sponsor: Indiana University
- Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Sponsor: Indiana University
- Early Diabetes Intervention Program
Sponsor: Indiana University
Industry payments
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
57.7%Insulin Analog57.7%Lantus Solostar100%Part D<11 patientsCardiovascular
42.3%Statin42.3%Atorvastatin Calcium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
8 NIH research awards on record, funded 2003–2018 per NIH RePORTER. The latest:
- 14/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 – Research Project
Indiana University Indianapolis
FY2018$348,830U01DK048406 - Cardiovascular effects of GLP-1 in obesity/metabolic syndrome
Indiana University Indianapolis
FY2017$660,047R01HL117620
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.
Diabetes, obesity & metabolism
Clinical Trial2026 - Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.
Diabetes, obesity & metabolism
Clinical Trial2026 - Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.
Diabetes, obesity & metabolism
Clinical Trial2025 - Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.
Diabetes, obesity & metabolism
Clinical Trial2025 - A Post-Hoc Analysis of Depressive Disorders in Patients with Type 2 Diabetes.
Healthcare (Basel, Switzerland)
Article2025
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
informaconnect.com/tides-europe/speakers/kieren-mather-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →informaconnect.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- Board Certified
Endocrinology, Diabetes & Metabolism (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
Division of Endocrinology & Metabolism, Indiana University School of Medicine (Indianapolis, IN), retained academic appointment from prior 20-year IU faculty career
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Media & interviews
press, podcasts and appearances- Confirmed speaker
TIDES Europe 2026 (Oligonucleotide and Peptide Therapeutics conference), presenting on Oral GLP-1 Clinical Program / Amylin Phase 2 Program Update, Nov 5
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →informaconnect.com ↗ - Featured interview
"What's Coming Next for GLP-1 and Metabolic Disease Treatment," The Physiologist Magazine (American Physiological Society), May 2025, discusses Lilly's diabetes/obesity pipeline (tirzepatide …
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiology.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.